Ashutosh D Wechalekar

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Update on treatment of light chain amyloidosis
    Shameem Mahmood
    Haematologica 99:209-21. 2014
  2. doi request reprint A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
    Ashutosh D Wechalekar
    National Amyloidosis Centre, University College London Medical School, London, UK
    Blood 121:3420-7. 2013
  3. doi request reprint Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
    Christopher P Venner
    National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom
    Blood 119:4387-90. 2012
  4. ncbi request reprint Inflammatory bowel disease and systemic AA amyloidosis
    Prayman T Sattianayagam
    Department of Medicine, Centre for Amyloidosis and Acute Phase Proteins, National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    Dig Dis Sci 58:1689-97. 2013
  5. doi request reprint AA amyloidosis complicating the hereditary periodic fever syndromes
    Thirusha Lane
    National Amyloidosis Centre, University College London Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    Arthritis Rheum 65:1116-21. 2013
  6. doi request reprint Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant
    Prayman T Sattianayagam
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK
    Eur Heart J 33:1120-7. 2012
  7. pmc Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I
    Dorota Rowczenio
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London, London, England
    Am J Pathol 179:1978-87. 2011
  8. doi request reprint AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome
    Ashutosh D Wechalekar
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine Hampstead Campus, Royal Free and University College Medical School, London, United Kingdom
    Blood 112:4009-16. 2008
  9. pmc A prospective study of nutritional status in immunoglobulin light chain amyloidosis
    Prayman T Sattianayagam
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, University College London, UK
    Haematologica 98:136-40. 2013
  10. ncbi request reprint Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
    Hugh J B Goodman
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Royal Free and University College Medical Schools, Hampstead Campus, Royal Free Hospital, London, UK
    Br J Haematol 134:417-25. 2006

Collaborators

Detail Information

Publications22

  1. pmc Update on treatment of light chain amyloidosis
    Shameem Mahmood
    Haematologica 99:209-21. 2014
    ..This review focuses on the treatments for light chain amyloidosis, how these treatments have evolved over the years, improved patient risk stratification, toxicities encountered and future directions. ..
  2. doi request reprint A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
    Ashutosh D Wechalekar
    National Amyloidosis Centre, University College London Medical School, London, UK
    Blood 121:3420-7. 2013
    ..Outcome and organ function of stage III AL amyloidosis without very elevated NT-proBNP and low SBP is improved by a very good hematologic response to chemotherapy...
  3. doi request reprint Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
    Christopher P Venner
    National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom
    Blood 119:4387-90. 2012
    ..7% (94.4% in Mayo Stage III patients). CVD is a highly effective regimen producing durable responses in AL amyloidosis; the deep clonal responses may overcome poor prognosis in advanced-stage disease...
  4. ncbi request reprint Inflammatory bowel disease and systemic AA amyloidosis
    Prayman T Sattianayagam
    Department of Medicine, Centre for Amyloidosis and Acute Phase Proteins, National Amyloidosis Centre, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    Dig Dis Sci 58:1689-97. 2013
    ..AA amyloidosis is a potential cause of end-stage renal failure and mortality but little is known of the natural history of this condition in inflammatory bowel disease...
  5. doi request reprint AA amyloidosis complicating the hereditary periodic fever syndromes
    Thirusha Lane
    National Amyloidosis Centre, University College London Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    Arthritis Rheum 65:1116-21. 2013
    ..This study was undertaken to determine the characteristics, presentation, natural history, and response to treatment in 46 patients who had been referred for evaluation at the UK National Amyloidosis Centre...
  6. doi request reprint Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant
    Prayman T Sattianayagam
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK
    Eur Heart J 33:1120-7. 2012
    ..Here, we report the dominant cardiac phenotype and outcome of FAP associated with TTR Thr60Ala (T60A), the most common UK variant...
  7. pmc Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I
    Dorota Rowczenio
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London, London, England
    Am J Pathol 179:1978-87. 2011
    ....
  8. doi request reprint AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome
    Ashutosh D Wechalekar
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine Hampstead Campus, Royal Free and University College Medical School, London, United Kingdom
    Blood 112:4009-16. 2008
    ....
  9. pmc A prospective study of nutritional status in immunoglobulin light chain amyloidosis
    Prayman T Sattianayagam
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, University College London, UK
    Haematologica 98:136-40. 2013
    ..The PG-SGA score would be an appropriate tool to evaluate whether nutritional intervention could improve patient outcomes...
  10. ncbi request reprint Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
    Hugh J B Goodman
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Royal Free and University College Medical Schools, Hampstead Campus, Royal Free Hospital, London, UK
    Br J Haematol 134:417-25. 2006
    ....
  11. doi request reprint Systemic amyloidosis in England: an epidemiological study
    Jennifer H Pinney
    Department of Medicine, UK National Amyloidosis Centre, Royal Free and University College Medical School, London, UK
    Br J Haematol 161:525-32. 2013
    ..Although there are various limitations to this study, the available data suggest the incidence of systemic amyloidosis in England exceeds 0ยท8/100 000 of the population...
  12. ncbi request reprint Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
    Ashutosh D Wechalekar
    National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, UK
    Blood 109:457-64. 2007
    ..The clonal response rates to CTD reported here are higher than any previously reported nontransplantation regimen in AL amyloidosis, and risk adaptation allows its use in poorer risk patients. CTD merits prospective randomized study...
  13. doi request reprint Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation
    Ashutosh D Wechalekar
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine Hampstead Campus, Royal Free and University College Medical School, London, UK
    Nat Clin Pract Cardiovasc Med 6:128-33. 2009
    ..A 46-year-old Afro-Caribbean man presented with progressive dyspnea and recurrent syncope. Clinical examination revealed evidence of biventricular failure...
  14. ncbi request reprint Images in cardiovascular medicine. Intermittent loss of second heart sound
    Jayshree Joshi
    National Amyloidosis Centre, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF United Kingdom
    Circulation 114:e612-3. 2006
  15. doi request reprint Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study
    Sanjay M Banypersad
    The Heart Hospital, London, UK
    Circ Cardiovasc Imaging 6:34-9. 2013
    ..We used equilibrium contrast cardiovascular magnetic resonance (EQ-CMR) to quantify the cardiac interstitial compartment, measured as myocardial extracellular volume (ECV) fraction, hypothesizing it would reflect amyloid burden...
  16. ncbi request reprint Perspectives in treatment of AL amyloidosis
    Ashutosh D Wechalekar
    National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London, UK
    Br J Haematol 140:365-77. 2008
    ..At the same time, various new specific anti-amyloid drugs have shown (in early phase studies or animal models) some very promising results. This review attempts to highlight the challenges, controversies and progress in AL amyloidosis...
  17. doi request reprint Native T1 mapping in transthyretin amyloidosis
    Marianna Fontana
    The Heart Hospital, London, United Kingdom Institute of Cardiovascular Science, University College London, London, United Kingdom National Amyloidosis Centre, University College London, London, United Kingdom
    JACC Cardiovasc Imaging 7:157-65. 2014
    ....
  18. doi request reprint Imaging in systemic amyloidosis
    Sajitha Sachchithanantham
    Center for Amyloidosis and Acute Phase Proteins, University College London Medical School, London, UK
    Br Med Bull 107:41-56. 2013
    ..Non-invasive imaging modalities offer an easy way to evaluate whole-body amyloid burden, accurately identify organ involvement, quantify and monitor disease progression and response to treatment...
  19. doi request reprint Outcome in renal Al amyloidosis after chemotherapy
    Jennifer H Pinney
    National Amyloidosis Centre, Division of Medicine, University College London Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
    J Clin Oncol 29:674-81. 2011
    ..The purpose of this study was to evaluate the effect of chemotherapy on clinical outcome among patients with renal AL amyloidosis...
  20. ncbi request reprint An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis
    Anoop D Shah
    Department of Haematology, Royal Free Hospital, London, UK
    Int J Hematol 91:121-3. 2010
    ..There appears to be no indication for discontinuation of bortezomib treatment or dose alteration in such cases...
  21. ncbi request reprint Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis
    Julian D Gillmore
    National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, London, United Kingdom
    Blood 107:1227-9. 2006
    ..Heart transplantation followed by SCT is feasible in selected patients with cardiac AL amyloidosis and may confer substantial survival benefit...